Dmochowski Roger R
Rev Urol. 2005;7 Suppl 1(Suppl 1):S22-6.
Advances in materials technology, coupled with a heightened understanding of wound healing and tissue-materials interactions in the lower urinary tract, have led to the development of a variety of new urethral bulking agents that are expected to be available in the near future. Experience with such bulking agents continues to grow and study results are disseminated as more clinical trials are initiated and completed. The intention of this report is to review the characteristics and initial clinical results for one of these new agents: Tegresstrade mark Urethral Implant (C. R. Bard, Inc., Murray Hill, NJ). This material, with unique phase-change properties upon exposure to body temperature fluids, offers ease of injection and requires less volume for clinical effect than bovine collagen. Additionally, Tegress Urethral Implant performance in clinical trials has suggested improved durability and correspondingly higher continence and improvement rates versus bovine collagen. As these materials evolve, an understanding of preferential implant techniques is being gained also. Delivery method and implant site may prove to substantially alter the biologic activity of these compounds. As outlined in this review, experience with Tegress Implant resulted in changes in delivery technique that translated into improved materials and tissue interaction.
材料技术的进步，再加上对伤口愈合以及下尿路组织与材料相互作用的深入理解，促使了多种新型尿道填充剂的研发，预计这些填充剂将在不久的将来上市。随着更多临床试验的启动和完成，此类填充剂的使用经验不断积累，研究结果也得以传播。本报告旨在回顾其中一种新型填充剂——Tegresstrade mark尿道植入物（美国新泽西州默里山的C. R. Bard公司）的特性及初步临床结果。这种材料在接触体温流体时具有独特的相变特性，注射方便，与牛胶原蛋白相比，达到临床效果所需的体积更小。此外，Tegress尿道植入物在临床试验中的表现表明，与牛胶原蛋白相比，其耐用性有所提高，相应地，控尿率和改善率也更高。随着这些材料的不断发展，人们对优先植入技术也有了一定的认识。给药方式和植入部位可能会显著改变这些化合物的生物活性。正如本综述所述，使用Tegress植入物的经验导致了给药技术的改变，进而改善了材料与组织的相互作用。
